medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-3-60-66medsovet-2455Research ArticleЗАБОЛЕВАНИЯ КИШЕЧНИКАBOWEL DISEASESСиндром раздраженного кишечника в свете римских критериев IV пересмотра (2016 г.)Irritable bowel syndrome in view of the rome IV criteria (2016)ДичеваД. Т.DichevaD. T.

к.м.н.

PhD in medicine

АндреевД. Н.AndreevD. N.

к.м.н.

PhD in medicine

ЩеглановаМ. П.ScheglanovaM. P.Парцваниа-ВиноградоваЕ. В.Partsvania-VinogradovaE. V.Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииРоссияYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaRussian Federation201820042018036066Copyright © Дичева Д.Т., Андреев Д.Н., Щегланова М.П., Парцваниа-Виноградова Е.В., 20182018Дичева Д.Т., Андреев Д.Н., Щегланова М.П., Парцваниа-Виноградова Е.В.Dicheva D.T., Andreev D.N., Scheglanova M.P., Partsvania-Vinogradova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2455

В обзорной статье отражены современные представления о синдроме раздраженного кишечника (СРК), основанные на положениях Римского консенсуса IV пересмотра (2016 г.). Рассмотрены вопросы дефиниции, классификации, особенностей клинической картины и критериев диагностики СРК. Представлены актуальные данные о фармакотерапии СРК с позиций доказательной медицины.

The review article reflects a contemporary view of irritable bowel syndrome (IBS) based on the Rome IV Criteria (2016). The paper studies the matters of definition, classification, features of the clinical picture and diagnostic criteria for IBS. It outlines the real-time findings of the pharmacotherapy of IBS from the perspective of evidence-based medicine.

синдром раздраженного кишечникаРимские критерии IVдиагностикалечениеirritable bowel syndromeRome IV criteriadiagnosticstreatmentReferencesLacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology, 2016, 150: 1393–1407.Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology, 2016, 150: 1393–1407.Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med, 2017, 6(11). pii: E99.Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med, 2017, 6(11). pii: E99.Самсонов А.А., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека, 2014, 18: 7-14Samsonov AA, Andreev DN, Dicheva DT. Irritable bowel syndrome from the perspective of modern gastroenterology. Farmateka, 2014, 18: 7-14Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther, 2014, 40(9): 1023-34.Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther, 2014, 40(9): 1023-34.Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol, 2014, 6: 71-80.Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol, 2014, 6: 71-80.Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol, 2012, 10: 712–721.Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol, 2012, 10: 712–721.Маев И.В., Дичева Д.Т., Андреев Д.Н., Сенина Ю.С. Синдром раздраженного кишечника в практике гастроэнтеролога. В сб.: Актуальные вопросы ведомственной медицины. М., 2012: 83–8Maev IV, Dicheva DT, Andreev DN, Senina YuS. Irritable bowel syndrome in the practice of a gastroenterologist. In collected works: Current issues of departmental medicine. M., 2012: 83-8Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008, 103: 1229–1239.Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008, 103: 1229–1239.Halder SL, Locke GR 3rd, Schleck CD et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology, 2007, 133: 799–807.Halder SL, Locke GR 3rd, Schleck CD et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology, 2007, 133: 799–807.Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology, 1991, 100: 998.Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology, 1991, 100: 998.Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 2016, 150(6): 1257-61.Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 2016, 150(6): 1257-61.Маев И. В., Черемушкин С.В., Кучерявый Ю.А. Синдром раздраженного кишечника. Римские критерии IV. О роли висцеральной гиперчувствительности и способах ее коррекции. Методическое пособие. М., 2016Maev IV, Cheremushkin SV, Kucheryavy YuA. Irritable bowel syndrome. Rome IV criteria. On the role of visceral hypersensitivity and ways of its correction. Guidance manual. M., 2016.Андреев Д.Н., Заборовский А.В., Трухманов А.С. и др. Эволюция представлений о функциональных заболеваниях желудочно-кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). РЖГГК, 2017, 1: 4-11Andreev DN, Zaborovsky AV, Trukhmanov AS, et al. Evolution of ideas about functional diseases of the gastrointestinal tract in view of the revised Rome IV criteria (2016). RJGGK, 2017, 1: 4-11Spiegel BM, Bolus R, Agarwal N et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther, 2010, 32: 1275–1291.Spiegel BM, Bolus R, Agarwal N et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther, 2010, 32: 1275–1291.Palsson O, Heymen S, Whitehead WE. Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS). United Eur Gastroenterol J, 2014, 2: P405.Palsson O, Heymen S, Whitehead WE. Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS). United Eur Gastroenterol J, 2014, 2: P405.Begtrup LM, Engsbro AL, Kjeldsen J et al.A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol, 2013, 11: 956–962.Begtrup LM, Engsbro AL, Kjeldsen J et al.A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol, 2013, 11: 956–962.Андреев Д.Н., Самсонов А.А., Черемушкин С.В. Синдром раздраженного кишечника: критерии диагностики и подходы к терапии. Фарматека, 2014, 14: 6-11Andreev DN, Samsonov AA, Cheremushkin SV. Irritable bowel syndrome: diagnostic criteria and approaches to therapy. Farmateka, 2014, 14: 6-11Руководство по внутренней медицине. Под ред.: Г.П. Арутюнова, А.И. Мартынова, А.А. Спасского. Москва, 2015Guidelines for Internal Medicine. Edited by Arutyunova GP, Martynova AI, Spassky AA. Moscow, 2015.Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Функциональная диспепсия: эпидемиология, классификация, этиопатогенез, диагностика и лечение: научное досье. М.: СТ-Принт, 2015Maev IV, Kucheryavyy YuA, Andreev DN. Functional dyspepsia: epidemiology, classification, etiopathogenesis, diagnosis and treatment: scientific dossier. M.: ST-Print, 2015.Маев И.В., Дичева Д.Т., Щегланова М.П. и др. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016 г.). Гастроэнтерология. Приложение к журналу Consilium Medicum, 2016, 2: 5-10Maev IV, Dicheva DT, Scheglanova MP. Functional dyspepsia in view of the revised Rome IV criteria (2016). Gastroenterology. Appendix to the Journal Consilium Medicum, 2016, 2: 5-10Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol, 2010, 8: 401-9.Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol, 2010, 8: 401-9.Riegler G, Esposito I. Bristol scale stool form.A still valid help in medical practice and clinical research. Tech Coloproctol, 2001, 5(3): 163-4.Riegler G, Esposito I. Bristol scale stool form.A still valid help in medical practice and clinical research. Tech Coloproctol, 2001, 5(3): 163-4.Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther, 2012, 35: 350–359.Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther, 2012, 35: 350–359.Vandvik PO, Wilhelmsen I, Ihlebaek C et al. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical impli cations. Aliment Pharmacol Ther, 2004, 20: 1195–1203.Vandvik PO, Wilhelmsen I, Ihlebaek C et al. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical impli cations. Aliment Pharmacol Ther, 2004, 20: 1195–1203.Whitehead WE, Palsson OS, Levy RR et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol, 2007, 102: 2767–2776.Whitehead WE, Palsson OS, Levy RR et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol, 2007, 102: 2767–2776.Ford AC, BercikP, Morgan DG et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology, 2013, 145: 1262–1270.Ford AC, BercikP, Morgan DG et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology, 2013, 145: 1262–1270.Ford AC, Talley NJ, Veldhuyzen van Zanten SJ et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA, 2008, 300: 1793–1805.Ford AC, Talley NJ, Veldhuyzen van Zanten SJ et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA, 2008, 300: 1793–1805.Menees ST, Kurlander J, Goel A et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology, 2014, 146(Suppl): S194.Menees ST, Kurlander J, Goel A et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology, 2014, 146(Suppl): S194.Waugh N, Cummins E, Royle P et al. Faecal cal-protectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess, 2013, 17: 1–211.Waugh N, Cummins E, Royle P et al. Faecal cal-protectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess, 2013, 17: 1–211.Ghoshal UC, Srivastava D, Verma A et al. Tropical sprue in 2014: the new face of an old disease. Curr Gastroenterol Rep, 2014, 16: 391.Ghoshal UC, Srivastava D, Verma A et al. Tropical sprue in 2014: the new face of an old disease. Curr Gastroenterol Rep, 2014, 16: 391.Ющук Н.Д., Андреев Д.Н., Кучерявый Ю.А. Острая диарея у взрослых: актуальность проблемы и новые возможности терапии. Инфекционные болезни: новости, мнения, обучение, 2017, 4(21): 99-107Yushchuk ND, Andreev DN, Kucheryavyy YuA. Acute diarrhea in adults: the urgency of the problem and the new possibilities of therapy. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2017, 4 (21): 99-107Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Черёмушкин С.В. Эволюция представлений о микроскопическом колите. Терапевтический архив, 2015, 87(4): 69-76Maev IV, Kucheryavy YuA, Andreev DN, Cheryomushkin SV. Evolution of concepts for microscopic colitis. Terapevticheskiy arkhiv, 2015, 87 (4): 69-76Slattery SA, Niaz O, Azia Q et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther, 2015, 42: 3–11.Slattery SA, Niaz O, Azia Q et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther, 2015, 42: 3–11.Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV. Consilium Medicum, 2016, 8: 79-85Maev IV, Cheremushkin SV, Kucheryavy YuA, Cheremushkina NV. Irritable bowel syndrome. Rome IV criteria. Consilium Medicum, 2016, 8: 79-85.Андреев Д.Н., Дичева Д.Т. Современные немедикаментозные и фармакотерапевтические подходы к лечению синдрома раздраженного кишечника. Гастроэнтерология. Приложение к журналу Consilium Medicum, 2014, 2: 47-52Andreev DN, Dicheva DT. Modern non-pharmacological and pharmacotherapeutic approaches to the treatment of irritable bowel syndrome. Gastroentero logy. Appendix to the Journal Consilium Medicum, 2014, 2: 47-52./Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med., 1995, 122: 107.Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med., 1995, 122: 107.Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med, 1999, 107: 41–50.Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med, 1999, 107: 41–50.Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology, 1988, 95: 701–708.Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology, 1988, 95: 701–708.Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol, 2011, 106: 915–922.Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol, 2011, 106: 915–922.Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol, 2014, 109(Suppl 1): 2–27.Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol, 2014, 109(Suppl 1): 2–27.Hirshkowitz M, Whiton K, Albert SM et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health, 2015 Mar, 1(1): 40-43.Hirshkowitz M, Whiton K, Albert SM et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health, 2015 Mar, 1(1): 40-43.Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol, 2011, 106: 508–514.Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol, 2011, 106: 508–514.Vazquez-Roque MI, Camilleri M, Smyrk T et al.Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology, 2013, 144: 903–911.Vazquez-Roque MI, Camilleri M, Smyrk T et al.Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology, 2013, 144: 903–911.Казюлин А.Н., Дичева Д.Т., Русс И.С., Андреев Д.Н., Парцваниа-Виноградова Е.В. Диетотерапия со сниженным содержанием ферментируемых олигосахаридов, дисахаридов, моносахаридов и полиолов (fodmap) при синдроме раздраженного кишечника. Consilium Medicum, 2016, 18(8): 75-78Kazyulin AN, Dicheva DT, Russ IS, Andreev DN, Partzvania-Vinogradova EV. Dietotherapy with reduced content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (fodmap) in irritable bowel syndrome. Consilium Medicum, 2016, 18 (8): 75-78.Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am. J. Gastroenterol., 2013, 108: 707.Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am. J. Gastroenterol., 2013, 108: 707.Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y), 2012, 8(11): 739-45.Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y), 2012, 8(11): 739-45.Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol, 2014, 11(4): 256-66.Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol, 2014, 11(4): 256-66.Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr, 2012, 142(8): 1510-8.Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr, 2012, 142(8): 1510-8.Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol, 2010 Aug, 25(8): 1366-73.Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol, 2010 Aug, 25(8): 1366-73.Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 2014, 146: 67.Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 2014, 146: 67.Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск ХVIII. М.: Видокс, 2017Federal guidelines on the use of medicinal products (formulary system). Issue XVIII. Moscow: Vidoks, 2017Poynard T, Regimbeau C, Benhamou Y. Metaanalysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2001 Mar, 15(3): 355-61.Poynard T, Regimbeau C, Benhamou Y. Metaanalysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2001 Mar, 15(3): 355-61.Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex, 2012 Apr-Jun, 77(2): 82-90.Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex, 2012 Apr-Jun, 77(2): 82-90.Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic re view and meta-analysis. BMJ, 2008 Nov 13, 337: a2313.Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic re view and meta-analysis. BMJ, 2008 Nov 13, 337: a2313.Маев И.В., Самсонов А.А., Андреев Д.Н. Современный алгоритм ведения пациентов с синдромом хронического запора с позиций внедрения новых фармакологических препаратов. Фарматека, 2012, 13: 37-43Maev IV, Samsonov AA, Andreev DN. A modern algorithm for managing patients with chronic constipation syndrome from the perspective of introducing new pharmacological agents. Farmateka, 2012, 13: 37-43Кучерявый Ю.А., Андреев Д.Н., Черемушкин С.В. Хронический запор: актуальность, проблемы и современные возможности лечения. Consilium Medicum, 2017, 19(8): 116-120Kucheryavy YuA, Andreev DN, Cheremushkin SV. Chronic constipation: urgency, problems and modern treatment options. Consilium Medicum, 2017, 19 (8): 116-120.Маев И., Дичева Д., Андреев Д. Новые возможности лечения хронического запора. Врач, 2012, 3: 45-8Maev I., Dicheva D., Andreev D. New possibilities of treatment of chronic constipation. Vrach, 2012, 3: 45-8Lavo B, Stenstam M, Nielsen AL et al. Loperamide in treatment of irritable bowel syndrome— a double-blind placebo controlled study. Scand J Gastroenterol Suppl, 1987, 130: 77–80.Lavo B, Stenstam M, Nielsen AL et al. Loperamide in treatment of irritable bowel syndrome— a double-blind placebo controlled study. Scand J Gastroenterol Suppl, 1987, 130: 77–80.Laterza L, Ianiro G, Scoleri I et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother, 2015 Mar, 16(4): 607-15.Laterza L, Ianiro G, Scoleri I et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother, 2015 Mar, 16(4): 607-15.Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo), 2014 Sep, 67(9): 667-70.Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo), 2014 Sep, 67(9): 667-70.Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep, 2015, 5: 12693.Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep, 2015, 5: 12693.Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J. Gastroenterol, 2014, 20(10): 2456–69.Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J. Gastroenterol, 2014, 20(10): 2456–69.Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther, 2017 Mar, 45(5): 604-616.Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther, 2017 Mar, 45(5): 604-616.Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore), 2016 Jan, 95(4): e2534.Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore), 2016 Jan, 95(4): e2534.Schoenfeld P, Pimentel M, Chang L et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther, 2014 May, 39(10): 1161-8.Schoenfeld P, Pimentel M, Chang L et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther, 2014 May, 39(10): 1161-8.Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос. журн. гастроэнтерол. гепатол. колопроктол., 2017, 27(5): 76-93Ivashkin VT, Shelygin YuA, Baranskaya EK. et al. Clinical guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia on the Diagnosis and Treat ment of Irritable Bowel Syndrome. Ros. zhurn. gastroenterol. gepatol. koloproktol, 2017, 27 (5): 76-93.Sebastián Domingo JJ. Review of the role of pro-biotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017, 40(6): 417-429.Sebastián Domingo JJ. Review of the role of pro-biotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017, 40(6): 417-429.Zhang Y, Li L, Guo C et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol, 2016, 16(1): 62.Zhang Y, Li L, Guo C et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol, 2016, 16(1): 62.

The authors declare that there are no conflicts of interest present.